Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy

Inference of Population Structure Using Multilocus Genotype Data

Jonathan K. Pritchard, Matthew Stephens, Peter Donnelly · Genetics · 2000 · 34.3K citations · Full text

Life Sciences, Biostatistics, Genetics +13

Principal components analysis corrects for stratification in genome-wide association studies

Alkes L. Price, Nick J. Patterson, Robert M. Plenge et al. · Nature Genetics · 2006 · 10.7K citations

Public Health, Biostatistics, Genetics +12

The International HapMap Project

Richard A. Gibbs, John W. Belmont, Paul Hardenbol et al. · Nature · 2003 · 6.2K citations · Full text

Life Sciences, Genetics, Molecular Genetics +14

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

I. Craig Henderson, Donald A. Berry, George D. Demetri et al. · Journal of Clinical Oncology · 2003 · 1.3K citations

Medicine, Oncology, Pharmacology +17

Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Amylou C. Dueck, Tito R. Mendoza, Sandra A. Mitchell et al. · JAMA Oncology · 2015 · 1K citations · Full text

Pharmacy, Oncology, Outcomes Research +13